leading brands of glp-1 agonists in biopharma GLP Agonist Clinical Trial Pipeline Appears Robust With 20+ Mapping the effectiveness and risks
Description
Many in vivo and in vitro studies make use of Ex-4, a well-known orthosteric antagonist for the GLP-1R [27]
The results
doi: 10.1016/j.molmet.2021.101181 109 WillardFSDourosJDGabeMBShowalterADWainscottDBSuterTMet al
Ultimately, investors increased Eli Lilly's market capitalization by around $95 billion in one day after these results
Dejgaard TF, Frandsen CS, Kielgast U, Storling J, Overgaard AJ, Svane MS, et al
